• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    4/17/24 4:31:15 PM ET
    $AFIB
    $DHAI
    $FBIO
    $INVO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AFIB alert in real time by email

    Gainers

    • Trevena (NASDAQ:TRVN) shares increased by 27.0% to $0.51 during Wednesday's after-market session. The company's market cap stands at $9.2 million.
    • Mustang Bio (NASDAQ:MBIO) stock increased by 11.97% to $0.43. The company's market cap stands at $4.4 million.
    • SINTX Techs (NASDAQ:SINT) stock rose 10.32% to $0.04. The market value of their outstanding shares is at $5.0 million.
    • Fortress Biotech (NASDAQ:FBIO) stock moved upwards by 6.21% to $1.88. The market value of their outstanding shares is at $36.1 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) stock increased by 5.92% to $1.43. The company's market cap stands at $4.5 million.
    • Acutus Medical (NASDAQ:AFIB) shares moved upwards by 5.51% to $0.17. The company's market cap stands at $5.1 million.

    Losers

    • TRACON Pharma (NASDAQ:TCON) shares decreased by 16.6% to $1.91 during Wednesday's after-market session. The market value of their outstanding shares is at $4.3 million.
    • DIH Holding US (NASDAQ:DHAI) stock fell 14.05% to $1.04. The market value of their outstanding shares is at $42.1 million.
    • Virax Biolabs Group (NASDAQ:VRAX) shares fell 8.92% to $0.62. The company's market cap stands at $1.4 million.
    • Soligenix (NASDAQ:SNGX) shares declined by 7.85% to $0.47. The market value of their outstanding shares is at $4.9 million.
    • INVO Bioscience (NASDAQ:INVO) shares declined by 7.7% to $1.68. The market value of their outstanding shares is at $4.3 million. As per the press release, Q4 earnings came out yesterday.
    • ProKidney (NASDAQ:PROK) shares declined by 6.7% to $2.65. The company's market cap stands at $163.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AFIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFIB
    $DHAI
    $FBIO
    $INVO

    CompanyDatePrice TargetRatingAnalyst
    ProKidney Corp.
    $PROK
    12/16/2025$12.00Buy
    H.C. Wainwright
    ProKidney Corp.
    $PROK
    6/30/2025$1.00Neutral → Underperform
    BofA Securities
    Virax Biolabs Group Limited
    $VRAX
    3/31/2025$3.00Buy
    H.C. Wainwright
    ProKidney Corp.
    $PROK
    9/30/2024Neutral
    JP Morgan
    ProKidney Corp.
    $PROK
    9/10/2024$6.00Buy
    Guggenheim
    Fortress Biotech Inc.
    $FBIO
    3/15/2024$10.00Buy
    ROTH MKM
    ProKidney Corp.
    $PROK
    3/7/2024$3.00Equal-Weight
    Morgan Stanley
    ProKidney Corp.
    $PROK
    1/2/2024Buy → Neutral
    BofA Securities
    More analyst ratings

    $AFIB
    $DHAI
    $FBIO
    $INVO
    SEC Filings

    View All

    SEC Form 6-K filed by Virax Biolabs Group Limited

    6-K - Virax Biolabs Group Ltd (0001885827) (Filer)

    4/10/26 4:15:02 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form EFFECT filed by Soligenix Inc.

    EFFECT - SOLIGENIX, INC. (0000812796) (Filer)

    4/3/26 12:15:07 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Soligenix Inc.

    EFFECT - SOLIGENIX, INC. (0000812796) (Filer)

    4/3/26 12:15:04 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $DHAI
    $FBIO
    $INVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Jin David

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    4/1/26 4:05:13 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Haight Nelson M

    3 - Virax Biolabs Group Ltd (0001885827) (Issuer)

    3/31/26 3:15:09 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Rosenwald Lindsay A Md

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    3/20/26 4:05:13 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $DHAI
    $FBIO
    $INVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

    HyBryte™ demonstrates more rapid and robust treatment response compared toValchlor® during 12-week treatment coursePRINCETON, N.J., April 2, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the positive results of its comparability study evaluating HyBryte™ (synthetic hypericin) versus Valchlor® (mechlorethamine) for the treatment of cutaneous T-cell lymphoma (CTCL) have been published in Oncology and Therapy. 

    4/2/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

    ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million; Cyprium is also eligible to receive tiered royalties and up to approximately $128 million in aggregate sales milestones from Sentynl Therapeutics Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress remains eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on net sales of UNLOXCYT™ (cosibelimab-ipdl) MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an inno

    3/31/26 4:05:00 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation

    LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, with an issue date of 18 February 2026 and an expiry date of 17 February 2029. Highlights:Virax believes the strengthened quality framework supports its post-acute infection syndromes ("PAIS") strategy by strengthening readiness for regulated in vitro diagnostic (

    3/31/26 7:34:00 AM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AFIB
    $DHAI
    $FBIO
    $INVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on ProKidney Corp. with a new price target

    H.C. Wainwright initiated coverage of ProKidney Corp. with a rating of Buy and set a new price target of $12.00

    12/16/25 9:01:44 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ProKidney Corp. downgraded by BofA Securities with a new price target

    BofA Securities downgraded ProKidney Corp. from Neutral to Underperform and set a new price target of $1.00

    6/30/25 7:57:01 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Virax Biolabs Group Ltd. with a new price target

    H.C. Wainwright initiated coverage of Virax Biolabs Group Ltd. with a rating of Buy and set a new price target of $3.00

    3/31/25 8:25:16 AM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AFIB
    $DHAI
    $FBIO
    $INVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $AFIB
    $DHAI
    $FBIO
    $INVO
    Leadership Updates

    Live Leadership Updates

    View All

    ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

    WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer. In this role, Mr. Madison will drive ProKidney's commercial strategy as the Company advances towards the potential commercialization of rilparencel. "Greg is a seasoned commercial biopharma executive with a proven track record of building high-performing organizations, shaping strategy, and preparing innovative therapies for market," said Bruce Culleton, M.D., CEO of ProKidney. "He brings valuable operation

    3/25/26 4:01:00 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $AFIB
    $DHAI
    $FBIO
    $INVO
    Financials

    Live finance-specific insights

    View All

    Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

    ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million; Cyprium is also eligible to receive tiered royalties and up to approximately $128 million in aggregate sales milestones from Sentynl Therapeutics Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress remains eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on net sales of UNLOXCYT™ (cosibelimab-ipdl) MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an inno

    3/31/26 4:05:00 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced the closing of the sale of Cyprium's Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million. "The sale of the PRV by Cyprium is a transformational corporate transaction for both Cyprium and Fortress. As the majority shareholder of Cyprium, Fortress expects to receive over $100 million in proceeds from the transaction, which will enhance our financial flexibility to invest in business development and the continued advancement of our robust portfolio," said Lindsay A. Rosenwal

    3/30/26 4:05:00 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

    Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™ during FY2025 Payer access for Emrosi™ available to over 100 million U.S. commercial lives Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for t

    3/25/26 4:01:00 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $DHAI
    $FBIO
    $INVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care